0001213900-23-006196.txt : 20230130 0001213900-23-006196.hdr.sgml : 20230130 20230130213534 ACCESSION NUMBER: 0001213900-23-006196 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230126 FILED AS OF DATE: 20230130 DATE AS OF CHANGE: 20230130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kaswan Michael CENTRAL INDEX KEY: 0001324483 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39421 FILM NUMBER: 23570040 MAIL ADDRESS: STREET 1: KBL HEALTHCARE ACQUISITION CORP II STREET 2: 645 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Orchestra BioMed Holdings, Inc. CENTRAL INDEX KEY: 0001814114 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 150 UNION SQUARE DRIVE CITY: NEW HOPE STATE: PA ZIP: 18938 BUSINESS PHONE: 646-343-9298 MAIL ADDRESS: STREET 1: 150 UNION SQUARE DRIVE CITY: NEW HOPE STATE: PA ZIP: 18938 FORMER COMPANY: FORMER CONFORMED NAME: Health Sciences Acquisitions Corp 2 DATE OF NAME CHANGE: 20200603 4 1 ownership.xml X0306 4 2023-01-26 0 0001814114 Orchestra BioMed Holdings, Inc. OBIO 0001324483 Kaswan Michael C/O ORCHESTRA BIOMED HOLDINGS, INC. 150 UNION SQUARE DRIVE NEW HOPE PA 18938 0 1 0 0 Chief Financial Officer Common Stock, par value $0.0001 per share ("Common Stock") 2023-01-26 4 A 0 133545 A 133545 D Nonstatutory Stock Option (Right to Buy) 10.00 2023-01-26 4 A 0 192566 A 2032-08-25 Common Stock 192566 192566 D These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities. Received in the Business Combination in exchange for 287,194 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock"). The nonstatutory stock options have vested and will vest in equal installments over a three-year period on a quarterly basis on the last day of each quarter, starting with the end of the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022. Received in the Business Combination in exchange for a nonstatutory stock option to acquire 414,120 shares of Legacy Orchestra Common Stock for $4.65 per share. /s/ Matthew Schob, Attorney-in-Fact 2023-01-30